Zeon has invested in Optieum Biotechnologies, a developer of innovative CAR T cells. Optieum is aiming to commercialize the world’s first innovative CAR T cell therapy for solid tumors. One of the cancer therapies classified as gene therapy, the new therapy is based on the Eumbody System technology developed at Ehime University, which can efficiently produce chimeric antigen receptors (CAR)…
Please subscribe to read the full story.Subscribe
Already a member? Log in here
